92 related articles for article (PubMed ID: 12771645)
1. Is there an "ACE" in the hole for postcoronary artery bypass graft myocardial dysfunction?
Parrish JS; Amundson DE
Crit Care Med; 2003 May; 31(5):1591. PubMed ID: 12771645
[No Abstract] [Full Text] [Related]
2. Beneficial hemodynamic and renal effects of intravenous enalaprilat following coronary artery bypass surgery complicated by left ventricular dysfunction.
Wagner F; Yeter R; Bisson S; Siniawski H; Hetzer R
Crit Care Med; 2003 May; 31(5):1421-8. PubMed ID: 12771613
[TBL] [Abstract][Full Text] [Related]
3. Preoperative angiotensin-converting enzyme inhibitors protect myocardium from ischemia during coronary artery bypass graft surgery.
Benedetto U; Melina G; Capuano F; Comito C; Bianchini R; Simon C; Refice S; Angeloni E; Sinatra R
J Cardiovasc Med (Hagerstown); 2008 Nov; 9(11):1098-103. PubMed ID: 18852580
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease.
van Gilst WH; Warnica JW; Baillot R; Johnstone D; Calciu CD; Block P; Myers MG; Chocron S; Rouleau JL;
Am Heart J; 2006 Jun; 151(6):1240-6. PubMed ID: 16781228
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibitor and/or angiotensin receptor antagonist for the postmyocardial infarction patient.
Scott RL
Cardiol Clin; 2008 Feb; 26(1):73-7, vii. PubMed ID: 18312907
[TBL] [Abstract][Full Text] [Related]
6. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.
Masoudi FA; Rathore SS; Wang Y; Havranek EP; Curtis JP; Foody JM; Krumholz HM
Circulation; 2004 Aug; 110(6):724-31. PubMed ID: 15289383
[TBL] [Abstract][Full Text] [Related]
7. The use of angiotensin-converting enzyme inhibitors in patients undergoing coronary artery bypass graft surgery.
Lazar HL
Vascul Pharmacol; 2005 Feb; 42(3):119-23. PubMed ID: 15792929
[TBL] [Abstract][Full Text] [Related]
8. Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients.
Roy P; Bouchard J; Amyot R; Madore F
Am J Kidney Dis; 2006 Oct; 48(4):645-51. PubMed ID: 16997061
[TBL] [Abstract][Full Text] [Related]
9. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
[TBL] [Abstract][Full Text] [Related]
10. A hard look at angiotensin receptor blockers in heart failure.
Gring CN; Francis GS
J Am Coll Cardiol; 2004 Nov; 44(9):1841-6. PubMed ID: 15519017
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibitors, inhibition of brain and peripheral angiotensin-converting enzymes, and left ventricular dysfunction in rats after myocardial infarction.
Ahmad M; White R; Tan J; Huang BS; Leenen FH
J Cardiovasc Pharmacol; 2008 Jun; 51(6):565-72. PubMed ID: 18496146
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
[TBL] [Abstract][Full Text] [Related]
13. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
Ghanem FA; Movahed A
Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
[TBL] [Abstract][Full Text] [Related]
14. Did they lower stress in the trial? Or was it just wasted energy?
Sanders SP
J Am Coll Cardiol; 2005 Mar; 45(6):858-9. PubMed ID: 15766819
[No Abstract] [Full Text] [Related]
15. Left ventricular hypertrophy: a "factor of risk": mass is reversible, but is the risk?
Frohlich ED
J Am Coll Cardiol; 2004 Jun; 43(12):2216-8. PubMed ID: 15193682
[No Abstract] [Full Text] [Related]
16. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.
Goyal A; Alexander JH; Hafley GE; Graham SH; Mehta RH; Mack MJ; Wolf RK; Cohn LH; Kouchoukos NT; Harrington RA; Gennevois D; Gibson CM; Califf RM; Ferguson TB; Peterson ED;
Ann Thorac Surg; 2007 Mar; 83(3):993-1001. PubMed ID: 17307447
[TBL] [Abstract][Full Text] [Related]
17. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
[TBL] [Abstract][Full Text] [Related]
18. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
19. Role of angiotensin-converting enzyme inhibitors in the coronary artery bypass patient.
Lazar HL
Ann Thorac Surg; 2005 Mar; 79(3):1081-9. PubMed ID: 15734453
[TBL] [Abstract][Full Text] [Related]
20. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
